Gelonghui, May 10 | Novavax Pharmaceuticals (NVAX.US) U.S. stocks soared more than 34% before the market opened, trading at $6.
On the news, the company announced a multi-billion dollar cooperation agreement with French pharmaceutical giant Sanofi.
According to the agreement, the two parties will jointly commercialize Novavax\’s COVID-19 vaccine starting next year and jointly develop a combination vaccine against coronavirus and influenza.
The company\’s CEO, John Jacobs, said that this licensing agreement will help the company lift the continued operating warning issued previously.
In addition, Novavax Pharmaceuticals announced its first quarter results. Sales were US$93.855 million, a year-on-year increase of nearly 16%; loss per share was US$1.05, which was significantly narrowed from US$3.41 in the same period last year.
Novavax Pharmaceuticals surged over 34% before the market opened and reached a multi-billion dollar cooperation with Sanofi
Gelonghui, May 10 | Novavax Pharmaceuticals (NVAX.US) U.S. stocks surged over 34% before the market opened, trading at $6
Like (0)
Sweetgreen rose 16.3% before opening, Q1 revenue exceeds expectations, raises annual guidance
Previous
May 10, 2024 5:57 pm
Musk: Tesla will invest well over $500 million in Supercharger network
Next
May 10, 2024 5:57 pm